Upsher-Smith Launches Propafenone Hydrochloride Extended-Release Capsules
MAPLE GROVE, Minn., June 30, 2020 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Propafenone Hydrochloride Extended-Release Capsules in 225 mg, 325 mg and 425 mg strengths. Upsher-Smith's product is AB-rated to the branded product, RYTHMOL® SR (propafenone hydrochloride extended-release capsules)*.
The propafenone hydrochloride extended-release capsule market had U.S. sales of approximately $51 million for the 12 months ending May 2020 according to IQVIA.
For questions about ordering, please call Upsher-Smith at 1-800-654-2299.
Please refer to the full Prescribing Information, including Boxed Warning for Propafenone Hydrochloride Extended-Release Capsules here. You can also call 1-888-650-3789 to obtain a copy of the full Prescribing Information.
You are encouraged to report suspected adverse reactions to Upsher-Smith Laboratories, LLC at 1-855-899-9180 or to the FDA by visiting http://www.fda.gov/medwatch.
As Upsher-Smith begins its second century in business, the company enters a new ambitious era that has been accelerated by its 2017 acquisition by Sawai Pharmaceutical Co., Ltd. Upsher-Smith and Sawai plan to leverage each other for growth worldwide and embark on an exciting new chapter as they seek to deliver the best value for their stakeholders, and most importantly, Do More Good™ for the patients they serve. For more information, visit www.upsher-smith.com.
*RYTHMOL SR is a trademark owned by or licensed to the GSK group of companies.
Do More Good is a trademark of Upsher-Smith Laboratories, LLC.
View original content to download multimedia:http://www.prnewswire.com/news-releases/upsher-smith-launches-propafenone-hydrochloride-extended-release-capsules-301086220.html
SOURCE Upsher-Smith Laboratories, LLC